Routine once-weekly darbepoetin alfa administration is cost-effective in lung cancer patients with chemotherapy-induced anemia: A Markov analysis

Markov Models in Medical Decision Making

Frank A. Sonnenberg, J. Robert Beck · Medical Decision Making · 1993 · 2.4K citations

Engineering, Prognosis, Markov Decision Processes +21

Prospective Randomized Trial of Docetaxel Versus Best Supportive Care in Patients With Non–Small-Cell Lung Cancer Previously Treated With Platinum-Based Chemotherapy

Frances A. Shepherd, Janet Dancey, Rodryg Ramlau et al. · Journal of Clinical Oncology · 2000 · 2.2K citations

Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. Procrit Study Group.

George D. Demetri, Mark G. Kris, James L. Wade et al. · Journal of Clinical Oncology · 1998 · 756 citations

Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. Procrit Study Group.

John A. Glaspy, Ronald Bukowski, Douglas Steinberg et al. · Journal of Clinical Oncology · 1997 · 705 citations

Clinical Evaluation of Once-Weekly Dosing of Epoetin Alfa in Chemotherapy Patients: Improvements in Hemoglobin and Quality of Life Are Similar to Three-Times-Weekly Dosing

Janice Gabrilove, Charles S. Cleeland, Robert B. Livingston et al. · Journal of Clinical Oncology · 2001 · 596 citations